Search Results - "PERREN, T. J."

Mucinous epithelial ovarian carcinoma by Perren, T J

“…Mucinous tumours involving the ovary may be benign, borderline, or malignant. Malignant tumours may be primary or metastatic. Differentiation between primary…”
Get full text

Clinical utility of complex multi-platform profiling in metastatic cancer patients by Garcia Foncillas, J., Aftimos, P.G., Barthelemy, P., Bellmunt, J., Berchem, G., Camps, C., de las Peñas, R., Finzel, A., Hervonen, J.P., Joensuu, T., Kong, A., Mackay, J., Mikropoulos, C., Mokbel, K., Mouysset, J.-L., Perren, T.-J., Guitti, G., Laes, J.-F.

Get full text

Feasibility and Compliance of Automated Measurement of Quality of Life in Oncology Practice by WRIGHT, E. P, SELBY, P. J, GOULD, A, CULL, A, CRAWFORD, M, GILLIBRAND, A, JOHNSTON, C, PERREN, T. J, RUSH, R, SMITH, A, VELIKOVA, G, WATSON, K

“…Systematic quality-of-life (QOL) assessment may have value in oncology practice by increasing awareness of a wide range of issues, possibly increasing…”
Get full text

Women with peritoneal carcinomatosis of unknown origin: efficacy of image‐guided biopsy to determine site‐specific diagnosis by Hewitt, MJ, Anderson, K, Hall, GD, Weston, M, Hutson, R, Wilkinson, N, Perren, TJ, Lane, G, Spencer, JA

“…Objectives  To evaluate the use of image‐guided biopsy (IGB) in routine clinical practice to obtain site‐specific diagnoses in women presenting with peritoneal…”
Get full text

Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study by HALL, G. D, BROWN, J. M, PERREN, T. J, COLEMAN, R. E, STEAD, M, METCALF, K. S, PEEL, K. R, POOLE, C, CRAWFORD, M, HANCOCK, B, SELBY, P. J

“…A randomised phase III trial was conducted to assess the role of interferon-alpha (INFalpha) 2a as maintenance therapy following surgery and/or chemotherapy in…”
Get full text

Vascular endothelial growth factor (VEGF) in breast cancer : Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen by ADAMS, J, CARDER, P. J, CAIRNDUFF, F, SELBY, P. J, PERREN, T. J, LANSDOWN, M, BANKS, R. E, DOWNEY, S, FORBES, M. A, MACLENNAN, K, ALLGAR, V, KAUFMAN, S, HALLAM, S, BICKNELL, R, WALKER, J. J

“…The assessment of angiogenesis in breast cancer is of importance as a key indicator of survival and response to therapy. Circulating vascular endothelial…”
Get full text

A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial by Smith, I. E., A’Hern, R. P., Coombes, G. A., Howell, A., Ebbs, S. R., Hickish, T. F., O’Brien, M. E. R., Mansi, J. L., Wilson, C. B., Robinson, A. C., Murray, P. A., Price, C. G. A., Perren, T. J., Laing, R. W., Bliss, J. M.

“…Background: To compare the efficacy of continuous infusional 5-fluorouracil (5-FU)-based chemotherapy against conventional bolus chemotherapy in the…”
Get full text

Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: The ITS Study by Thorpe, H, Brown, S R, Sainsbury, J R, Perren, T J, Hiley, V, Dowsett, M, Nejim, A, Brown, J M

“…The effect of breast cancer surgery timing during the menstrual cycle on prognosis remains controversial. We conducted a multicentre prospective study to…”
Get full text

Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies by BANKS, R. E, GEARING, A. J. H, HEMINGWAY, I. K, NORFOLK, D. R, PERREN, T. J, SELBY, P. J

“…Cellular adhesion molecules have been implicated in tumour progression and metastasis. This study examines for the first time the serum concentrations of…”
Get full text

Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation by DENT, J, HALL, G. D, WILKINSON, N, PERREN, T. J, RICHMOND, I, MARKHAM, A. F, MURPHY, H, BELL, S. M

“…Ovarian clear cell carcinoma (OCCC) accounts for a small but significant proportion of all ovarian cancers and is a distinct clinical and pathological entity…”
Get full text

c-erbB-2 oncogene as a prognostic marker in breast cancer by PERREN, T. J

Get full text

Detection of colorectal cancer cells in peripheral blood by reverse‐transcriptase polymerase chain reaction for cytokeratin 20 by Wyld, David K., Selby, Peter, Perren, Timothy J., Jonas, Sonja K., Allen‐Mersh, Timothy G., Wheeldon, John, Burchill, Susan A.

“…The staging of colorectal cancer currently depends on pathological examination of the surgical specimen and regional lymph nodes, accompanied by imaging tests…”
Get full text

Clinical outcomes according to age and comorbidities in the OSCAR UK observational study of front-line bevacizumab (BEV)-containing therapy for advanced ovarian cancer (aOC) by Hall, M., Bertelli, G., Li, L., Green, C., Chan, S., Yeoh, C.C., Hasan, J., Ograbek, A., Perren, T.J.

Get full text

The acute phase protein response in patients receiving subcutaneous IL‐6 by BANKS, R. E., FORBES, M. A., STORR, M., HIGGINSON, J., THOMPSON, D., RAYNES, J., ILLINGWORTH, J. M., PERREN, T. J., SELBY, P. J., WHICHER, J. T.

“…SUMMARY IL‐6, tumour necrosis factor‐α (TNE‐α) and IL‐1 are thought to be the key mediators of the acute phase response although much of the evidence is based…”
Get full text

Peritoneal carcinomatosis: image-guided peritoneal core biopsy for tumor type and patient care by Spencer, J A, Swift, S E, Wilkinson, N, Boon, A P, Lane, G, Perren, T J

“…To assess image-guided peritoneal core biopsy for the diagnosis of tumor type and treatment of patients with peritoneal carcinomatosis. Thirty-five women (age…”
Get more information

Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study by HUMPHREYS, A. C, DENT, J, RODWELL, S, CRAWFORD, S. M, JOFFE, J. K, BRADLEY, C, DODWELL, D, PERREN, T. J

“…This study was originally designed as a phase I/II study, with a dose escalation of docetaxel in combination with epirubicin 50 mg m(-2) and 5-fluorouracil…”
Get full text

Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment by Clamp, A.R., McNeish, I.A., Dean, A., Gallardo-Rincon, D., Kim, J.-W., O’Donnell, D.M., Hook, J., Blagden, S., Brenton, J.D., Naik, R., Perren, T.J., Sundar, S., Cook, A.D., James, E.C., Gabra, H., Lord, R., Hall, M., Dark, G., Kaplan, R.S., Ledermann, J.A.

Get full text

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial by Ledermann, J.A., Embleton-Thirsk, A.C., Perren, T.J., Jayson, G.C., Rustin, G.J.S., Kaye, S.B., Hirte, H., Oza, A., Vaughan, M., Friedlander, M., González-Martín, A., Deane, E., Popoola, B., Farrelly, L., Swart, A.M., Kaplan, R.S., Parmar, M.K.B.

“…Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance…”
Get full text

Anthracycline-induced cardiomyopathy in siblings with early breast cancer by Young, A.C., Mercer, B., Perren, T.J., Dodwell, D.

Get full text

Block sequential adriamycin CMF - optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? by CAMERON, D. A, ANDERSON, A, CROWN, J, LEONARD, R. C. F, TOY, E, EVANS, T. R. J, LE VAY, J. H, KENNEDY, I. C. S, GRIEVE, R. J, PERREN, T. J, JONES, A, MANSI, J

“…After the publication of the 10-year survival data from Milan on the adjuvant use of the block sequential regimen consisting of four cycles of adriamycin…”
Get full text